The global trabectedin market is expected to grow at a significant CAGR during the forecast period (2021-2027). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships and collaborations, mergers and acquisitions, geographical expansion, new product launches, to remain competitive in the marketplace. For instance, in November 2020, STADA Arzneimittel AG’s subsidiary in the United Arab Emirates (UAE), STADA MENA DWC-LLC, announced a commercial licensing agreement for Yondelis (trabectedin) in Algeria, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, Tunisia, United Arab Emirates (UAE), and Yemen. PharmaMar received a non-disclosed upfront payment as well as subsequent remunerations, including a regulatory milestone payment, under the terms of the license and commercialization agreement.
To Request a Sample of our Report on Trabectedin Market: https://www.omrglobal.com/request-sample/trabectedin-market
PharmaMar kept exclusive production rights to trabectedin and sell it to STADA for clinical and commercial use in the 15 MENA markets on an exclusive basis. This new agreement follows PharmaMar’s announcement on August 26th, 2019, regarding the agreement reached with Janssen Products LP (Janssen), under which PharmaMar regained commercialization rights to the product in more than 40 countries where Yondelis has already been approved, which were previously licensed to Janssen. Yondelis is now approved for the treatment of soft tissue sarcoma and recurrent ovarian cancer in various MENA countries. STADA was granted exclusive rights to sell and distribute the product in MENA nations as a result of licensing agreement and the official transfer of marketing authorizations.In August 2020, Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has begun commercialization of Yondelis in Canada, following the receipt of a Notice of Compliance from Health Canada approving the transfer of the commercial rights to Valeo. PharmaMar S.A., based in Madrid, Spain, manufactures Yondelis (trabectedin), a new marine-derived anticancer agent. As Yondelis is a globally recognised standard of care in the treatment of soft tissue sarcoma, the goal of the company was to raise awareness of its benefits and availability throughout Canada.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Product
- By Application
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Johnson & Johnson Services, Inc., and Pharma Mar, S.A., among others.
(Get 15% Discount on Buying this Report)
A full Report of Trabectedin Market is Available @ https://www.omrglobal.com/industry-reports/trabectedin-market
Global Trabectedin Market Report by Segment
By Product
- Purity:98%-99%
- Purity:99%
By Application
- Breast Cancer Treatment
- Ovarian Cancer Treatment
- Pediatric Sarcoma Treatment
- Others
Global Trabectedin Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
